Krka, d. d. (WSE:KRK)

Market Cap	29.78B +41.9%
Revenue (ttm)	8.57B +5.7%
Net Income	1.70B +10.8%
EPS	55.56 +11.6%
Shares Out	n/a
PE Ratio	17.50
Forward PE	17.40
Dividend	35.03 (3.74%)
Ex-Dividend Date	Jul 22, 2025

Volume	29
Average Volume	85
Open	988.00
Previous Close	972.00
Day's Range	970.00 - 988.00
52-Week Range	640.00 - 1,100.00
Beta	0.47
RSI	46.07
Earnings Date	Mar 12, 2026

About Krka, d. d.

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company’s prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolism, central nervous system, oncology, pain relief, antiinfectives for systemic use, antidiabetics, and other products. It provides non-prescription prod...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1954
• Employees: 13,107
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: KRK

Financial Performance

In 2024, Krka, d. d.'s revenue was 1.91 billion, an increase of 5.71% compared to the previous year's 1.81 billion. Earnings were 356.99 million, an increase of 13.71%.

Financial numbers in EUR